Hidradenitis Suppurativa

Promising phase 2 data for LY3041658 released during the Late-breaking Research session at the 2023 annual meeting.

Expert insights on the latest issues in wounds as well as HS resources are shared at the annual meeting.

Researchers say disease severity, site, and comorbidities may lower a patient’s quality of life as they navigate hidradenitis suppurativa.

Following a systematic review and observational study meta-analysis, researchers have uncovered an association between hidradenitis suppurativa and several atopic diseases.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Newly released safety and efficacy data on Novartis’ secukinumab for hidradenitis suppurativa is published in The Lancet.

This is the first phase 3 evidence to suggest the drug as a promising treatment approach in adult patients.

Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.

At the 2022 Fall Clinical Dermatology Conference, Joslyn R. Sciacca Kirby, MD, MS, MEd, and Raj Chovatiya, MD, PhD, discussed how there is a large unmet need for hidradenitis suppurativa treatment and what future treatment could look like.

SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.

Study data was presented at EADV 2022 regarding socioeconomic status related to HS.

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

Click here to answer this week's poll.

Theodore Rosen, MD, details his top tips for treating hidradenitis suppurativa.

This painful skin disease may lower the odds of live birth and trigger comorbidities.

In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."

Almirall announced today that it will work with the University of Michigan to better understand disease drivers in hidradenitis suppurativa.

Clinical trials investigate biologics, JAK inhibitors, and additional systemic treatments as first-line alternatives to or adjuvant therapies alongside surgery.

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.

A retrospective cohort study published in the International Journal of American Academy of Dermatology investigated the possible association between atopic dermatitis and hidradenitis suppurativa.

In this week’s Pointers with Dr Portela, the 208SkinDoc watches several TikTok videos in which creators share their experience with hidradenitis suppurativa.

Ginette A. Okoye, MD, FAAD, provides several clinical pearls to help physicians find the best therapy for their individual hidradenitis suppurativa patients in her presentation at the Skin of Color Update 2021.

Many conditions are different in the pediatric population than in the adult population. How does hidradenitis suppurativa differ between the 2 groups?

Though investigators called for more research on the biologic, recent data showed patients treated with bimekizumab recorded improved skin pain when compared to placebo and adalimumab.

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.